The filing, dated November 13, reads as corporate romance novels often begin: with a sudden acquisition. Yet here, no damsel in distress, only a firm weathering a 20% decline while the S&P 500 basks in 15% growth. The market, that fickle bard, sings no ballads of Fluor’s $15.59 billion revenue or its $3.38 billion net income. Instead, it hums a dirge.
As the holiday season jingles along merrily, Mr. Hoskinson finds himself in the curious position of defending his honor against the slings and arrows of outrageous fortune-specifically, the wild claims that he had a hand in ADA’s staggering 80% nosedive over the past four years. It seems the man took to X on Christmas Day, not to don a Santa hat but to deliver a message of buoyancy for 2026, urging his fellow ADA aficionados not to toss their hats into the ring of despair just yet. 🎩
After a rather original drop, price rebound and headed towards the territory between the $0.115-$0.116 mark, at which point sellers’ pressure appeared. This zone was some sort of temporary resistance, and the rejection resulted in sideways movement. 🧠 It’s like trying to open a jar of pickles with a spoon made of jelly. You’re not gonna get anywhere.
The relentless bull rally that gold and silver are experiencing is raising concerns among financial analysts, who believe that something may have broken. A recession might be just around the corner, some analysts predict. Or perhaps they’ve just discovered the concept of “normal” and are now terrified. 🤯
The stock had pulled a Houdini-up 113% in a year, laughing at the S&P’s meek 15% crawl. UroGen’s market cap swelled to $1.1 billion, a ghost of a thing built on $96.52 million in revenue and a net loss wider than the Grand Canyon. But Wall Street’s circus never rewards the clowns who stay on the tightrope too long.
The Seven, in their hubris, have claimed nearly a third of the index’s valuation-a dominion forged in the fires of artificial intelligence hype and the delusion that innovation alone justifies endless multiples. Yet, as Solzhenitsyn once dissected the Soviet machine, so too must we interrogate the mechanisms of their power: What if the AI-driven future they promise is but a mirage, a desert mirage where investors have been made to kneel?
Like a shy debutante, XRP has modestly waltzed up by a mere 0.47% since yesterday-still waiting for its big break.
According to the esteemed CoinGlass (which sounds like a shiny, collectible ornament, but is apparently a serious crypto tracker), over a day, investors committed an eye-watering $1.44 billion USD worth of DOGE in futures contracts. That’s enough to rebrand a small country or, at least, almost enough to buy another yacht. This surge indicates an enthusiasm that’s been missing since the days of feathered hats and flapper dresses. Apparently, the speculative appetite for DOGE is back, perhaps fueled by a cocktail of optimism and the enduring charm of internet doggos. 🐕🦺
Grandeur Peak didn’t just trim a position – they committed a cardinal sin of investment etiquette. You don’t just leave a 3.69% holding in a life sciences darling. You don’t reduce your stake to 0.15% and expect to be invited back to the 13F AUM mixer. It’s like showing up to a wedding in a tank top – technically allowed, spiritually offensive. Now Bruker’s relegated to the “also bought a toaster” section of their portfolio, while NASDAQ:MPWR gets 8.05% of assets like it’s the guest of honor.
When the Securities and Exchange Commission’s scroll unrolled on November 13, it revealed more than numbers. Here was a seedling of conviction-a 1.89% bet against the frost of market skepticism. The fund’s portfolio, now 104 positions strong, cradles this newcomer like a sapling in winter. The top holdings-MPWR, FROG, MRX-stand as ancient oaks by comparison, their roots deep in the soil of institutional confidence.